RT Journal Article SR Electronic T1 Cervical cancer: a new era JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP ijgc-2024-005579 DO 10.1136/ijgc-2024-005579 A1 Caruso, Giuseppe A1 Wagar, Matthew K A1 Hsu, Heng-Cheng A1 Hoegl, Jorge A1 Rey Valzacchi, Guido Martin A1 Fernandes, Andreina A1 Cucinella, Giuseppe A1 Sahin Aker, Seda A1 Jayraj, Aarthi S A1 Mauro, Jessica A1 Pareja, Rene A1 Ramirez, Pedro T YR 2024 UL http://ijgc.bmj.com/content/early/2024/08/07/ijgc-2024-005579.abstract AB Cervical cancer is a major global health issue, ranking as the fourth most common cancer in women worldwide. Depending on stage, histology, and patient factors, the standard management of cervical cancer is a combination of treatment approaches, including (fertility- or non-fertility-sparing) surgery, radiotherapy, platinum-based chemotherapy, and novel systemic therapies such as bevacizumab, immune checkpoint inhibitors, and antibody-drug conjugates. While ambitious global initiatives seek to eliminate cervical cancer as a public health problem, the management of cervical cancer continues to evolve with major advances in imaging modalities, surgical approaches, identification of histopathological risk factors, radiotherapy techniques, and biomarker-driven personalized therapies. In particular, the introduction of immune checkpoint inhibitors has dramatically altered the treatment of cervical cancer, leading to significant survival benefits in both locally advanced and metastatic/recurrent settings. As the landscape of cervical cancer therapies continues to evolve, the aim of the present review is to provide a comprehensive discussion of the current state and the latest practice-changing updates in cervical cancer.